Drug Patents owned by Eyevance

1. Drug name - TOBRADEX ST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450287 EYEVANCE Topical ophthalmic compositions containing tobramycin and dexamethasone Dec, 2027

(5 years from now)

US8101582 EYEVANCE Topical ophthalmic compositions containing tobramycin and dexamethasone Dec, 2027

(5 years from now)

US7795316 EYEVANCE Topical ophthalmic compositions containing tobramycin and dexamethasone Aug, 2028

(5 years from now)

Drugs and Companies using DEXAMETHASONE; TOBRAMYCIN ingredient

Treatment: Use of a combination of tobramycin and dexamethasone to treat ocular inflammation where an infection or risk of infection exists

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.05%;0.3% SUSPENSION/DROPS;OPHTHALMIC Prescription

2. Drug name - ZERVIATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993471 EYEVANCE Ophthalmic formulations of cetirizine and methods of use Mar, 2030

(7 years from now)

US8829005 EYEVANCE Ophthalmic formulations of cetirizine and methods of use Mar, 2030

(7 years from now)

US9750684 EYEVANCE Ophthalmic formulations of cetirizine and methods of use Mar, 2030

(7 years from now)

US8829005

(Pediatric)

EYEVANCE Ophthalmic formulations of cetirizine and methods of use Sep, 2030

(7 years from now)

US9254286 EYEVANCE Ophthalmic formulations of cetirizine and methods of use Jul, 2032

(9 years from now)

US9254286

(Pediatric)

EYEVANCE Ophthalmic formulations of cetirizine and methods of use Jan, 2033

(10 years from now)

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.24% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.